Research Analysts’ updated eps estimates for Tuesday, October 22nd:
Amgen (NASDAQ:AMGN) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $405.00 target price on the stock.
Anika Therapeutics (NASDAQ:ANIK) had its outperform rating reaffirmed by analysts at Barrington Research. Barrington Research currently has a $37.00 target price on the stock.
Biomea Fusion (NASDAQ:BMEA) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $40.00 price target on the stock.
BOK Financial (NASDAQ:BOKF) had its neutral rating reissued by analysts at Wedbush. They currently have a $115.00 price target on the stock.
Cheesecake Factory (NASDAQ:CAKE) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $50.00 target price on the stock.
Cheesecake Factory (NASDAQ:CAKE) had its outperform rating reiterated by analysts at Wedbush. They currently have a $45.00 target price on the stock.
Cibus (NASDAQ:CBUS) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. The firm currently has a $20.00 price target on the stock.
CareDx (NASDAQ:CDNA) had its neutral rating reissued by analysts at HC Wainwright.
Cidara Therapeutics (NASDAQ:CDTX) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $24.00 target price on the stock.
Gatos Silver (NYSE:GATO) had its hold rating reaffirmed by analysts at Canaccord Genuity Group Inc..
IAMGOLD (NYSE:IAG) (TSE:IMG) had its sector perform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $6.00 target price on the stock.
Inter Parfums (NASDAQ:IPAR) had its buy rating reaffirmed by analysts at DA Davidson. They currently have a $163.00 target price on the stock.
Largo (NYSE:LGO) had its buy rating reissued by analysts at HC Wainwright. They currently have a $4.40 price target on the stock.
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $390.00 target price on the stock.
Medpace (NASDAQ:MEDP) had its outperform rating reissued by analysts at William Blair.
Nuvation Bio (NYSE:NUVB) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $5.00 target price on the stock.
PulteGroup (NYSE:PHM) had its neutral rating reaffirmed by analysts at Wedbush. Wedbush currently has a $115.00 price target on the stock.
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its overweight rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $116.00 price target on the stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $1,260.00 price target on the stock.
REGENXBIO (NASDAQ:RGNX) had its buy rating reissued by analysts at Chardan Capital. They currently have a $52.00 target price on the stock.
Roku (NASDAQ:ROKU) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $100.00 price target on the stock.
SecureWorks (NASDAQ:SCWX) had its hold rating reissued by analysts at Needham & Company LLC.
Sangamo Therapeutics (NASDAQ:SGMO) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $5.00 price target on the stock.
Synopsys (NASDAQ:SNPS) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $640.00 price target on the stock.
TriNet Group (NYSE:TNET) had its underweight rating reissued by analysts at JPMorgan Chase & Co.. They currently have a $103.00 target price on the stock.
Trevi Therapeutics (NASDAQ:TRVI) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock.
Wintrust Financial (NASDAQ:WTFC) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $130.00 target price on the stock.
Zillow Group (NASDAQ:ZG) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $66.00 price target on the stock.
Zymeworks (NYSE:ZYME) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $12.00 target price on the stock.
Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.